Welcome to our dedicated page for SBC Medical Group Holdings Incorporated news (Ticker: SBC), a resource for investors and traders seeking the latest updates and insights on SBC Medical Group Holdings Incorporated stock.
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) is frequently featured in financial and industry news as a global provider of consulting and management services to medical corporations and their clinics. News coverage of SBC often focuses on its expansion in aesthetic medicine, its multi-brand clinic strategy, and its capital markets activity as a Nasdaq-listed company included in the Russell 3000 Index.
Readers following SBC Medical news can expect updates on international expansion initiatives, such as partnerships and consulting agreements in markets like Thailand and Singapore, and strategic moves in the United States. Recent announcements include a strategic minority equity investment and collaboration framework with OrangeTwist, a U.S.-based MedSpa chain, marking SBC’s formal entry into the U.S. medical aesthetics market. News also covers partnerships with regional operators like BLEZ ASIA in Thailand, where SBC provides management support and clinical protocol guidance for new dermatology-focused clinics.
Another major category of SBC news involves corporate and capital strategy. The company issues press releases on quarterly financial results, including revenue trends, operating income, EBITDA, and key operating metrics such as the number of franchise locations and customer visits. SBC also reports on its capital strategy, including the effectiveness of a shelf registration statement on Form S-3 and authorization of a share repurchase program, as well as its inclusion in major equity indexes.
In addition, SBC news highlights strategic investments and acquisitions, such as tender offers for shares of Waqoo, Inc., a regenerative medicine-focused research and development company. These transactions are presented as part of SBC’s broader plan to enhance its healthcare technology capabilities and support long-term growth in aesthetic and related medical fields. Investors and observers can use this news feed to monitor SBC’s clinic network growth, international partnerships, and financial performance over time.
SBC Medical (Nasdaq: SBC) is rolling out its aesthetic healthcare interpretation app Talk Bridge across all Shonan Beauty Clinic locations and expanding English support via an in-house interpretation center, a new Global Beauty Advisor (GBA) role, and upgraded English digital marketing.
The program aims to improve service for English-speaking inbound customers, scale interpretation capacity (from ~300 to a targeted 800 sessions/month), and streamline booking via a redesigned English website and Instagram funnel.
SBC Medical Group (NASDAQ:SBC) was covered in a Flash Report dated April 22, 2026, which reiterated a Buy-Extended rating and maintained a 12-month price target of $9.00 versus an April 21, 2026 share price of $3.65.
The report attributes recent volatility to a secondary share issuance that reduced the founder's stake by ~3% without diluting shareholders, notes a potential public float increase to ~20%, cites a strong net cash position, and highlights management's target to return to revenue growth in 2026 alongside international M&A and AI-driven initiatives.
SBC (Nasdaq: SBC) announced the closing of a previously disclosed underwritten secondary public offering of 3,100,000 shares by Dr. Yoshiyuki Aikawa at a public offering price of $3.25 per share on April 21, 2026. Proceeds to the selling stockholder were approximately $10.1 million before underwriting discounts and commissions. The Company did not sell any shares and received no proceeds. Maxim Group acted as sole book-running manager and Roth Capital Partners as co-manager. The offering was made under the company’s effective Form S-3 shelf registration and final prospectus supplement has been filed with the SEC.
SBC Medical Group Holdings (Nasdaq: SBC) announced the pricing of a secondary offering of 3,100,000 shares by selling stockholder Dr. Yoshiyuki Aikawa at $3.25 per share, with an underwriter option for up to 465,000 additional shares. The offering is expected to close on or about April 21, 2026. The company is not selling any shares and will not receive proceeds; all proceeds go to the selling stockholder. Maxim Group is sole book-runner; Roth Capital Partners is co-manager. The offering is being made under the company's effective Form S-3 shelf registration.
SBC Medical Group (Nasdaq:SBC) reiterated a Buy-Extended rating with a 12-month price target of $9.00 after reporting Q4:25 results. Q4 revenue fell to about $39.6M due to 2025 franchise fee changes, while operating and net income improved and cash totaled approximately $164M. The firm expects revenue stabilization and modest growth in 2026 as SBC pursues operational efficiency, international expansion, AI initiatives, and selective M&A.
SBC Medical (Nasdaq: SBC) reported Q4 2025 and full-year results on March 27, 2026. Q4 revenue was $40 million (-11% YoY) and Q4 EPS was $0.14 (+133% YoY). Full-year revenue was $174 million (-15% YoY) with net income $51 million (+9% YoY) and EPS $0.50 (+4% YoY).
EBITDA was $70 million for FY2025 (-21% YoY) and EBITDA margin was 40% (down 3 percentage points). Franchise locations reached 283 and annual customer visits were 6.63 million. Management emphasized structural changes and priorities for 2026 including multi-brand dermatology and international expansion.
SBC Medical (Nasdaq: SBC) launched SBC Wellness 2.0, a wellness and longevity platform combining aesthetic healthcare, preventative care, and data-driven health management.
The program targets the longevity market projected at about $800B in 2025 and $2T by 2035, and will leverage SBC Medical’s 283 clinics and ~6.5 million annual visits in Japan to build subscription-like corporate contracts and self-pay services.
SBC Medical (Nasdaq: SBC) will open the flagship NEO Skin Clinic Ginza on March 28, 2026, in a prime location near GINZA SIX. The clinic features VIP rooms for international clients, leverages a network of 283 affiliated clinics (as of Dec 2025), and builds on the Ebisu validation from April 2025.
The brand uses VISIA skin diagnostics, appoints Japanese and Korean technical advisors, offers internationally aligned pricing, and plans further expansion into Nagoya and Kobe by end-2026 to support multi-brand growth and higher-value services.
SBC Medical (Nasdaq: SBC) will report fourth-quarter and full-year 2025 financial results before U.S. market open on March 27, 2026.
Management will host an earnings conference call on March 27, 2026 at 8:30 a.m. ET with prepared remarks and a Q&A. The earnings release, slides, and archived webcast will be posted on the company investor relations website.
SBC Medical (Nasdaq: SBC) appointed Sheng-FU Hsiao as Chief Technology Officer effective March 1, 2026, to lead an AI-driven digital transformation across 283 global locations and leverage data from 6.63 million annual patient visits to build a scalable Automated Management Infrastructure.
Key initiatives include AI call centers, core system modernization to microservices, expanded back-office automation, an "AI Concierge," "AI Mirrors," and global rollout of an AI-native medical OS to improve productivity, transparency, and reproducibility.